Chief Executive Stephane Bancel says Moderna will work with the Trump administration. Moderna stock rose in midday trades.

Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...

Q4 2024 Management View Moderna CEO Stéphane Bancel highlighted 2024 as a year of significant progress, with revenues reaching $3.2 billion. The company reduced operating expenses by $2.6 billion and ...

A social media post claims that Moderna’s CEO confessed to creating a COVID vaccine before the pandemic. After fact checking, ...

Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, ...

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

In its fourth-quarter earnings report, Moderna’s revenue was down substantially from 2023. Separately, media reports reveal anticipated cuts to the company’s digital team.

An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...

Reports Q4 revenue $966M, consensus $941.14M. The company reported $923M in Spikevax sales in the fourth quarter of 2024 and $15M in mRESVIA ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...

Moderna reported mixed fourth quarter earnings and full-year 2024 earnings Friday. Moderna's stock was down 5% in premarket ...